Integer Holdings Corporation
ITGR
$126.38
+0.08%
Integer Holdings Corporation is a leading manufacturer of medical device components and subassemblies, serving original equipment manufacturers (OEMs) across the medical technology industry. The company operates as a single segment with three primary product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets, with a strong presence in the United States and operations in Ireland, Puerto Rico, Costa Rica, and other global locations. Integer is a critical partner to major medical device companies, providing complex, high-precision components that are essential to life-saving devices. The current investor narrative centers on a strategic review announced in early 2026 that could potentially lead to a sale of the company at a premium, which has driven significant stock appreciation and heightened analyst attention following strong quarterly results and multiple upgrades.…
ITGR
Integer Holdings Corporation
$126.38
Related headlines
Investment Opinion: Should I buy ITGR Today?
Rating: Hold. The stock is a solid company with strong growth prospects, but the current price already reflects much of the optimism. The average analyst target of $121.80 is below the current price, suggesting limited upside. The strategic review could provide a catalyst, but the outcome is uncertain.
Supporting evidence includes forward PE of 18.42x, which is reasonable if earnings grow as expected, and revenue growth to $2.23 billion. The company's operating margin of 11.33% and net margin of 5.57% demonstrate profitability. However, the stock trades at a premium to its historical valuation, and the PEG ratio is negative, indicating potential overvaluation. The low beta of 0.613 provides some downside protection.
Key risks include the strategic review failing to result in a sale, which could lead to a -20% decline to the low target. Additionally, if revenue growth decelerates below 10%, the forward PE would expand, making the stock expensive. This Hold would upgrade to Buy if the stock pulls back to around $110 or if the strategic review results in a sale above $130. Conversely, it would downgrade to Sell if the strategic review is terminated and the stock breaks below $100. Overall, the stock is fairly valued relative to its growth prospects, but not a bargain at current levels.
Sign up to view all
ITGR 12-Month Price Forecast
The AI stance is bullish with medium confidence. The company's strong operational performance and the strategic review provide upside potential, but the stock's current valuation limits margin of safety. Key factors include robust revenue growth, improving profitability, and the potential for a sale at a premium. However, the stock's price above the average analyst target suggests that much of the good news is priced in. The stance would be upgraded to high confidence if the strategic review results in a definitive sale agreement, and downgraded to neutral if the review is terminated or growth decelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Integer Holdings Corporation's 12-month outlook, with a consensus price target around $121.80 and implied upside of -3.6% versus the current price.
Average Target
$121.80
0 analysts
Implied Upside
-3.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$101 - $127
Analyst target range
The wide spread between the low and high targets ($26.00) reflects significant uncertainty regarding the outcome of the strategic review and the potential for a sale at a premium. The low target of $101.00 likely assumes that the strategic review does not result in a sale and that the company's growth normalizes, while the high target of $127.00 prices in a successful sale or continued strong operational performance. Recent news indicates that analysts have been upgrading the stock following the Q4 earnings beat and the announcement of the strategic review, suggesting a positive shift in sentiment. However, the current price exceeding the average target suggests that the market has already priced in much of the optimism, and investors should be cautious about chasing the stock at these levels.
Drowning in data?
Find the real signal!
Bulls vs Bears: ITGR Investment Factors
Integer Holdings presents a compelling bull case driven by the strategic review's potential for a premium acquisition, strong revenue growth, and improving profitability. However, the stock's current price already reflects much of this optimism, trading above the average analyst target. The bear case centers on valuation risk and the uncertainty of the strategic review outcome. Currently, the bull case has stronger evidence given the company's operational momentum and the likelihood of a sale, but the most important tension is whether the strategic review concludes successfully or not—this single factor will determine whether the stock moves toward the high target or falls to the low target.
Bullish
- Strategic review potential: The company announced a strategic review in early 2026 that could lead to a sale at a premium. This has driven a 64.76% YTD stock surge and attracted analyst upgrades, with the high target at $127.00.
- Strong revenue growth: Forward revenue estimate is $2.23 billion, reflecting solid growth. The company's revenue is diversified across Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets, reducing concentration risk.
- Improving profitability: Operating margin is 11.33% and net margin is 5.57%, indicating healthy profitability for a manufacturing-focused business. ROE of 5.88% and ROA of 3.86% show efficient capital use.
- Undervalued on forward earnings: Forward PE of 18.42x is well below the trailing PE of 26.50x, implying expected earnings growth of ~44%. This suggests the market is pricing in significant future earnings expansion.
Bearish
- Stock trades above average target: Current price of $126.50 exceeds the average analyst target of $121.80, implying limited upside of -3.7% if the stock reverts to that level. This suggests much of the optimism is already priced in.
- High valuation on trailing earnings: Trailing PE of 26.50x is elevated, and the PEG ratio is negative (-1.49) due to expected earnings decline, indicating potential overvaluation if growth does not materialize as expected.
- Strategic review uncertainty: The wide range between low ($101) and high ($127) analyst targets reflects significant uncertainty about the outcome. If no sale occurs, the stock could fall sharply to the low target, a 20% downside.
- Thin net margins: Net margin of 5.57% is relatively low, leaving limited room for error. Any cost inflation or pricing pressure could disproportionately impact profitability.
ITGR Technical Analysis
Integer Holdings has been in a powerful uptrend over the past year, with the stock price surging 18.67% over the last 12 months and an impressive 64.76% gain year-to-date. The current price of $126.50 sits near the top of its 52-week range, at approximately 99.8% of the high of $126.795, indicating strong momentum and bullish sentiment. This positioning near the highs suggests the market is rewarding the company's operational performance and the potential for a strategic transaction, though it also raises concerns about overextension in the short term.
Beta
0.61
0.61x market volatility
Max Drawdown
-42.7%
Largest decline past year
52-Week Range
$62-$127
Price range past year
Annual Return
+22.3%
Cumulative gain past year
| Period | ITGR Return | S&P 500 |
|---|---|---|
| 1m | +0.9% | +1.0% |
| 3m | +41.1% | +5.4% |
| 6m | +45.7% | +17.8% |
| 1y | +22.3% | +16.5% |
| ytd | +64.6% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ITGR Fundamental Analysis
Integer Holdings has demonstrated robust revenue growth, with the most recent quarterly revenue estimated at $2.23 billion (annualized) and a forward revenue estimate of $2.23 billion, reflecting a solid growth trajectory. The company's gross margin stands at 23.06%, while operating margin is 11.33%, indicating healthy profitability relative to its manufacturing-focused business model. Net income is positive, with a net margin of 5.57%, and the company has achieved a return on equity of 5.88% and return on assets of 3.86%, showcasing efficient use of capital.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ITGR Overvalued?
Given that Integer Holdings is profitable with positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE is 26.50x, while the forward PE is 18.42x, indicating that the market expects significant earnings growth in the coming year. The gap between trailing and forward PE suggests a forward earnings growth rate of approximately 44%, which is optimistic but supported by the company's recent performance and strategic review potential.
PE
26.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a moderate debt-to-equity ratio of 0.80, which could strain cash flows if interest rates rise. The company's net margin of 5.57% is thin, leaving limited buffer against cost increases. Revenue concentration in the medical device OEM market exposes it to customer consolidation and pricing pressures. However, a current ratio of 3.32 provides ample liquidity to meet short-term obligations, and the low beta of 0.613 suggests stable earnings relative to the market.
Market and competitive risks include the potential for valuation compression if the strategic review fails to result in a sale, as the stock trades at a premium to its historical average. The medical device industry faces regulatory scrutiny and competitive pressures from larger players. The stock's 64.76% YTD surge has outpaced the S&P 500's 12.94% gain, creating risk of profit-taking. Recent news highlights analyst upgrades, but a negative outcome from the strategic review could trigger downgrades and a sharp sell-off.
In a worst-case scenario, if the strategic review concludes without a sale and the company's growth decelerates, the stock could fall to the 52-week low of $62.00, representing a -51% downside from the current price of $126.50. Even the analyst low target of $101.00 implies a -20% loss. The maximum drawdown of -42.74% over the past year illustrates the potential for significant losses in adverse conditions. Investors should be prepared for high volatility around the strategic review's outcome.
